Concurrent Investment Advisors LLC Purchases 2,319 Shares of Becton, Dickinson and Company $BDX

Concurrent Investment Advisors LLC boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 20.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,742 shares of the medical instruments supplier’s stock after purchasing an additional 2,319 shares during the period. Concurrent Investment Advisors LLC’s holdings in Becton, Dickinson and Company were worth $2,367,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in BDX. Vanguard Group Inc. increased its position in shares of Becton, Dickinson and Company by 4.7% during the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after acquiring an additional 1,259,750 shares during the period. T. Rowe Price Investment Management Inc. increased its position in shares of Becton, Dickinson and Company by 3.7% during the first quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier’s stock worth $2,880,510,000 after acquiring an additional 448,644 shares during the period. Massachusetts Financial Services Co. MA increased its position in shares of Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock worth $1,567,654,000 after acquiring an additional 667,957 shares during the period. JPMorgan Chase & Co. increased its position in shares of Becton, Dickinson and Company by 7.6% during the first quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier’s stock worth $1,012,649,000 after acquiring an additional 312,124 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Becton, Dickinson and Company by 1.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier’s stock worth $707,872,000 after acquiring an additional 37,733 shares during the period. Institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on BDX shares. Wells Fargo & Company raised their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Royal Bank Of Canada began coverage on shares of Becton, Dickinson and Company in a research report on Thursday, September 25th. They set a “sector perform” rating and a $211.00 target price on the stock. Morgan Stanley lifted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Finally, Argus lifted their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $188.31 on Wednesday. The firm has a market cap of $53.97 billion, a price-to-earnings ratio of 33.87, a PEG ratio of 1.46 and a beta of 0.25. The company’s 50 day moving average is $190.46 and its 200 day moving average is $185.47. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion for the quarter. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s payout ratio is currently 74.82%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,023 shares of company stock worth $562,036 over the last ninety days. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.